Bayer AG (BAYRY) announced an update on their ongoing clinical study.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The phase 2 study “A Study to Learn How Well the Drug Larotrectinib Works in Adults With Different Solid Cancers With a Change in the Genes Called NTRK Fusion” aims to see how well Bayer’s larotrectinib treats solid tumors that share this rare gene change. The trial matters because it supports a tumor-agnostic strategy, which can extend the drug’s reach across many cancer types and age groups.
The sole treatment in this trial is larotrectinib, also known as BAY2757556, Vitrakvi, or LOXO-101, given as an oral capsule or liquid. It is designed to block NTRK gene signaling in cancer cells, with the goal of shrinking tumors or keeping them from growing in patients whose tumors carry NTRK fusions.
This is an interventional phase 2 study using a non-randomized, parallel-group design, where all enrolled patients receive larotrectinib in separate cohorts based on tumor type. There is no placebo or active comparator, and the trial is open-label, meaning both doctors and patients know they are getting the study drug, with the main aim being cancer treatment, not prevention or diagnosis.
The trial was first submitted on October 12, 2015, marking the start of formal regulatory tracking and patient recruitment plans. The study is now listed as completed, and the last update to the record on April 27, 2026, signals that Bayer has refreshed the dataset, likely including follow-up or analysis milestones relevant for longer-term outcomes.
For investors, the latest update supports the durability of Bayer’s position in the niche but growing NTRK inhibitor market, where Vitrakvi competes with Roche’s entrectinib and emerging next-generation agents. A clear, updated phase 2 dataset can help defend pricing, support label expansions, and stabilize sentiment around BAYRY’s oncology portfolio, though the narrow patient population limits absolute revenue upside.
In summary, this Bayer-sponsored trial of larotrectinib in NTRK fusion-positive solid tumors is completed and recently updated, with more detailed information available on the ClinicalTrials portal.
To learn more about BAYRY’s potential, visit the Bayer AG drug pipeline page.